Exact Mass: 489.1686
Exact Mass Matches: 489.1686
Found 500 metabolites which its exact mass value is equals to given mass value 489.1686
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
OA-6129 E
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
(1S,2S,3R,5S,8R,9R,10R)-10-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylic acid
4-Hydroxy duloxetine glucuronide
4-Hydroxy duloxetine glucuronide is a metabolite of duloxetine. Duloxetine (sold under the brand names Cymbalta, Ariclaim, Xeristar, Yentreve, Duzela) is a serotonin-norepinephrine reuptake inhibitor (SNRI) manufactured and marketed by Eli Lilly. It is effective for major depressive disorder and generalized anxiety disorder (GAD). (Wikipedia)
3-Benzyl-1-(1H-imidazol-4-ylmethyl)-4-(thien-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile
Gemigliptin
(2S)-3-[3-[(4-Carbamimidoylbenzoyl)amino]propanoylamino]-2-[(4-ethylphenyl)sulfonylamino]propanoic acid
O1-[2-(2-amino-4-oxo-3,4-dihydro-pteridin-6-yl)-1-(1,2,3-dihydroxy-propyl)-ethyl]-beta-D-glucopyranuronic acid
Gln Asp Val Glu
Asn Val Glu Glu
Val Glu Asn Glu
Gln Val Asp Glu
Glu Asn Val Glu
8-2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-deoxyguanosine
Ala Asp Glu Arg
Ala Asp Arg Glu
Ala Glu Asp Arg
Ala Glu Arg Asp
Ala Arg Asp Glu
Ala Arg Glu Asp
Cys Cys His Lys
Cys Cys His Gln
Cys Cys Lys His
Cys Cys Gln His
Cys Asp Pro Arg
Cys Asp Arg Pro
Cys His Cys Lys
Cys His Cys Gln
Cys His Lys Cys
Cys His Gln Cys
Cys Lys Cys His
Cys Lys His Cys
Cys Pro Asp Arg
Cys Pro Arg Asp
Cys Gln Cys His
Cys Gln His Cys
Cys Arg Asp Pro
Cys Arg Pro Asp
Asp Ala Glu Arg
Asp Ala Arg Glu
Asp Cys Pro Arg
Asp Cys Arg Pro
Asp Asp Ile Gln
Asp Asp Leu Gln
Asp Asp Gln Ile
Asp Asp Gln Leu
Asp Glu Ala Arg
Asp Glu Ile Asn
Asp Glu Leu Asn
Asp Glu Asn Ile
Asp Glu Asn Leu
Asp Glu Gln Val
Asp Glu Arg Ala
Asp Glu Val Gln
Asp Ile Asp Gln
Asp Ile Glu Asn
Asp Ile Asn Glu
Asp Ile Gln Asp
Asp Lys Asn Asn
Asp Leu Asp Gln
Asp Leu Glu Asn
Asp Leu Asn Glu
Asp Leu Gln Asp
Asp Met Pro Gln
Asp Met Gln Pro
Asp Asn Glu Ile
Asp Asn Glu Leu
Asp Asn Ile Glu
Asp Asn Lys Asn
Asp Asn Leu Glu
Asp Asn Asn Lys
Asp Asn Asn Gln
Asp Asn Gln Asn
Asp Pro Cys Arg
Asp Pro Met Gln
Asp Pro Gln Met
Asp Pro Arg Cys
Asp Gln Asp Ile
Asp Gln Asp Leu
Asp Gln Glu Val
Asp Gln Ile Asp
Asp Gln Leu Asp
Asp Gln Met Pro
Asp Gln Asn Asn
Asp Gln Pro Met
Asp Gln Val Glu
Asp Arg Ala Glu
Asp Arg Cys Pro
Asp Arg Glu Ala
Asp Arg Pro Cys
Asp Val Glu Gln
Asp Val Gln Glu
Glu Ala Asp Arg
Glu Ala Arg Asp
Glu Asp Ala Arg
Glu Asp Ile Asn
Glu Asp Leu Asn
Glu Asp Asn Ile
Glu Asp Asn Leu
Glu Asp Gln Val
Glu Asp Arg Ala
Glu Asp Val Gln
Glu Glu Gly Arg
Glu Glu Asn Val
Glu Glu Arg Gly
Glu Glu Val Asn
Glu Gly Glu Arg
Glu Gly Arg Glu
Glu Ile Asp Asn
Glu Ile Asn Asp
Glu Leu Asp Asn
Glu Leu Asn Asp
Glu Met Asn Pro
Glu Met Pro Asn
Glu Asn Asp Ile
Glu Asn Asp Leu
Glu Asn Glu Val
Glu Asn Ile Asp
Glu Asn Leu Asp
Glu Asn Met Pro
Glu Asn Asn Asn
Glu Asn Pro Met
Glu Pro Met Asn
Glu Pro Asn Met
Glu Gln Asp Val
Glu Gln Val Asp
Glu Arg Ala Asp
Glu Arg Asp Ala
Glu Arg Glu Gly
Glu Arg Gly Glu
Glu Val Asp Gln
Glu Val Glu Asn
Glu Val Asn Glu
Glu Val Gln Asp
Gly Glu Glu Arg
Gly Glu Arg Glu
Gly His Asn Tyr
Gly His Tyr Asn
Gly Met Pro Trp
Gly Met Trp Pro
Gly Asn His Tyr
Gly Asn Asn Trp
Gly Asn Trp Asn
Gly Asn Tyr His
Gly Pro Met Trp
Gly Pro Trp Met
Gly Arg Glu Glu
Gly Trp Met Pro
Gly Trp Asn Asn
Gly Trp Pro Met
Gly Tyr His Asn
Gly Tyr Asn His
His Cys Cys Lys
His Cys Cys Gln
His Cys Lys Cys
His Cys Gln Cys
His Gly Asn Tyr
His Gly Tyr Asn
His Lys Cys Cys
His Asn Gly Tyr
His Asn Tyr Gly
His Gln Cys Cys
His Tyr Gly Asn
His Tyr Asn Gly
Ile Asp Asp Gln
Ile Asp Glu Asn
Ile Asp Asn Glu
Ile Asp Gln Asp
Ile Glu Asp Asn
Ile Glu Asn Asp
Ile Asn Asp Glu
Ile Asn Glu Asp
Ile Gln Asp Asp
Lys Cys Cys His
Lys Cys His Cys
Lys Asp Asn Asn
Lys His Cys Cys
Lys Asn Asp Asn
Lys Asn Asn Asp
Leu Asp Asp Gln
Leu Asp Glu Asn
Leu Asp Asn Glu
Leu Asp Gln Asp
Leu Glu Asp Asn
Leu Glu Asn Asp
Leu Asn Asp Glu
Leu Asn Glu Asp
Leu Gln Asp Asp
Met Asp Pro Gln
Met Asp Gln Pro
Met Glu Asn Pro
Met Glu Pro Asn
Met Gly Pro Trp
Met Gly Trp Pro
Met Asn Glu Pro
Met Asn Pro Glu
Met Pro Asp Gln
Met Pro Glu Asn
Met Pro Gly Trp
Met Pro Asn Glu
Met Pro Gln Asp
Met Pro Trp Gly
Met Gln Asp Pro
Met Gln Pro Asp
Met Trp Gly Pro
Met Trp Pro Gly
Asn Asp Glu Ile
Asn Asp Glu Leu
Asn Asp Ile Glu
Asn Asp Lys Asn
Asn Asp Leu Glu
Asn Asp Asn Lys
Asn Asp Asn Gln
Asn Asp Gln Asn
Asn Glu Asp Ile
Asn Glu Asp Leu
Asn Glu Glu Val
Asn Glu Ile Asp
Asn Glu Leu Asp
Asn Glu Met Pro
Asn Glu Asn Asn
Asn Glu Pro Met
Asn Glu Val Glu
Asn Gly His Tyr
Asn Gly Asn Trp
Asn Gly Trp Asn
Asn Gly Tyr His
Asn His Gly Tyr
Asn His Tyr Gly
Asn Ile Asp Glu
Asn Ile Glu Asp
Asn Lys Asp Asn
Asn Lys Asn Asp
Asn Leu Asp Glu
Asn Leu Glu Asp
Asn Met Glu Pro
Asn Met Pro Glu
Asn Asn Asp Lys
Asn Asn Asp Gln
Asn Asn Glu Asn
Asn Asn Gly Trp
Asn Asn Lys Asp
Asn Asn Asn Glu
Asn Asn Gln Asp
Asn Asn Trp Gly
Asn Pro Glu Met
Asn Pro Met Glu
Asn Gln Asp Asn
Asn Gln Asn Asp
Asn Gln Gln Thr
Asn Gln Thr Gln
Asn Thr Gln Gln
Asn Trp Gly Asn
Asn Trp Asn Gly
Asn Tyr Gly His
Asn Tyr His Gly
Pro Cys Asp Arg
Pro Cys Arg Asp
Pro Asp Cys Arg
Pro Asp Met Gln
Pro Asp Gln Met
Pro Asp Arg Cys
Pro Glu Met Asn
Pro Glu Asn Met
Pro Gly Met Trp
Pro Gly Trp Met
Pro Met Asp Gln
Pro Met Glu Asn
Pro Met Gly Trp
Pro Met Asn Glu
Pro Met Gln Asp
Pro Met Trp Gly
Pro Asn Glu Met
Pro Asn Met Glu
Pro Gln Asp Met
Pro Gln Met Asp
Pro Arg Cys Asp
Pro Arg Asp Cys
Pro Trp Gly Met
Pro Trp Met Gly
Gln Cys Cys His
Gln Cys His Cys
Gln Asp Asp Ile
Gln Asp Asp Leu
Gln Asp Glu Val
Gln Asp Ile Asp
Gln Asp Leu Asp
Gln Asp Met Pro
Gln Asp Asn Asn
Gln Asp Pro Met
Gln Glu Asp Val
Gln Glu Val Asp
Gln His Cys Cys
Gln Ile Asp Asp
Gln Leu Asp Asp
Gln Met Asp Pro
Gln Met Pro Asp
Gln Asn Asp Asn
Gln Asn Asn Asp
Gln Asn Gln Thr
Gln Asn Thr Gln
Gln Pro Asp Met
Gln Pro Met Asp
Gln Gln Asn Thr
Gln Gln Gln Ser
Gln Gln Ser Gln
Gln Gln Thr Asn
Gln Ser Gln Gln
Gln Thr Asn Gln
Gln Thr Gln Asn
Gln Val Glu Asp
Arg Ala Asp Glu
Arg Ala Glu Asp
Arg Cys Asp Pro
Arg Cys Pro Asp
Arg Asp Ala Glu
Arg Asp Cys Pro
Arg Asp Glu Ala
Arg Asp Pro Cys
Arg Glu Ala Asp
Arg Glu Asp Ala
Arg Glu Glu Gly
Arg Glu Gly Glu
Arg Gly Glu Glu
Arg Pro Cys Asp
Arg Pro Asp Cys
Ser Gln Gln Gln
Val Asp Glu Gln
Val Asp Gln Glu
Val Glu Asp Gln
Val Glu Glu Asn
Val Glu Gln Asp
Val Asn Glu Glu
Val Gln Asp Glu
Val Gln Glu Asp
Trp Gly Met Pro
Trp Gly Asn Asn
Trp Gly Pro Met
Trp Met Gly Pro
Trp Met Pro Gly
Trp Asn Gly Asn
Trp Asn Asn Gly
Trp Pro Gly Met
Trp Pro Met Gly
Tyr Gly His Asn
Tyr Gly Asn His
Tyr His Gly Asn
Tyr His Asn Gly
Tyr Asn Gly His
Tyr Asn His Gly
N-(4-acetamidophenyl)-Indomethacin amide
BMS 214662
C471 - Enzyme Inhibitor > C2020 - Farnesyl Transferase Inhibitor
5-chloro-2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium methyl sulphate
1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
1-Octyl-2,3-dimethylimidazolium bis(trifluoromethanesulfonyl)imide
d-galactose 1-[2-(2-azidoethoxy)ethoxyethyl]-2,3,4,6-tetra-o-acetate
3-(3-amino-3-oxopropyl)-2-[[1-methyl-2-(p-tolyl)-1H-indol-3-yl]azo]benzothiazolium chloride
2-(4-METHYLUMBELLIFERYL)-α-D-N-ACETYLNEURAMINIC ACID SODIUM SALT
[(2R)-1-[6-(propan-2-yloxycarbonylamino)purin-9-yl]propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphinic acid
tert-Butyl (2S,5S)-2-(9-chloro-1,11-dihydroisochromeno[4,3:6,7]naphtho[1,2-d]imidazol-2-yl)-5-(methyl)pyrrolidine-1-carboxylate
2-Acetamido-1,3-di-O-benzyl-4,6-O-benzylidene-2-deoxy-b-D-glucopyranoside
Gemigliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
PRX-07034 hydrochloride
PRX-07034 hydrochloride is a highly selective and potent 5-HT6 receptor antagonist with a Ki= 4-8 nM and an IC50 of 19 nM. PRX-07034 can be used for the research of enhancing working memory and cognitive flexibility[1].
(2S,3S,4R,5R)-2-(5-tert-Butyl-1,3,4-oxadiazol-2-yl)-5-(6-(4-chloro-2-fluoro-anilino)purin-9-yl)tetrahydrofuran-3,4-diol
1-((1H-Imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile
5-(benzenesulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethylbenzenesulfonamide
N-[4-bromo-2-[[(2-hydrazinyl-2-oxoethyl)amino]-phenylmethyl]phenyl]-3-(4-morpholinyl)propanamide
[9-(4-Ethoxyphenyl)sulfonyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-(4-methylphenyl)methanone
2-[5-Methanesulfonylamino-2-(4-aminophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-n-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide
(3R,5S,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylic acid
(2S)-3-[3-[(4-Carbamimidoylbenzoyl)amino]propanoylamino]-2-[(4-ethylphenyl)sulfonylamino]propanoic acid
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-[4-(1-piperidinylsulfonyl)phenyl]benzamide
Asp-Leu-Asp-Gln
A tetrapeptide composed of L-aspartic acid, L-leucine, L-aspartic acid, and L-glutamine joined in sequence by peptide linkages.
4-[[3-[(4-Chlorophenyl)sulfonylamino]-2-quinoxalinyl]amino]-1-piperidinecarboxylic acid ethyl ester
3-[[4-(1-benzotriazolyl)-1-piperidinyl]sulfonyl]-N-cyclopentylbenzenesulfonamide
4-[3-[(3-chloro-4-fluoroanilino)-oxomethyl]-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid tert-butyl ester
[4-[2-(4-Methoxyphenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-phenylmethanone
1-[(4-chlorophenyl)-oxomethyl]-N-[4-(1-piperidinylsulfonyl)phenyl]-3-piperidinecarboxamide
4-[4-(4-acetylphenyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]-3-nitrobenzenesulfonamide
nocamycin E
An organic heterotricyclic compound and tetramic acid derivative isolated from a mutant strain of Saccharothrix syringae. Nocamycin E exhibits considerably lower antibacterial activity than the corresponding methyl ester, nocamycin I.
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(2-furanylmethyl)amino]-N-cyclohexyl-2-(2-fluorophenyl)acetamide
N-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(3-fluorophenyl)-N-(3-pyridinyl)butanediamide
1-O-[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoyl]-beta-D-glucopyranuronate
N-[[3-(4-carboxybutyl)-5-chloro-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-7-yl]carbonyl]-L-phenylalanine
(1S,9R,10R,11R)-12-acetyl-10-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
2-[(2S,3S,6S)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
(1R,9S,10S,11S)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methylsulfonyl-11-(piperidine-1-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R,3R,3aS,9bS)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
(1S,9R,10R,11R)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methylsulfonyl-11-(piperidine-1-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(1R,9S,10S,11S)-12-acetyl-10-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-5-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3S,3aR,9bR)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
2-[(2S,3R,6R)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(2S,3S,6R)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
4-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
[(3aR,4R,9bR)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
[(3aS,4S,9bS)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
N-[[(2R,3S)-8-[2-(3-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
2-[(2R,3S,6S)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(2R,3S,6R)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(2R,3R,6S)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(2R,3R,6R)-3-[[(2-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-phenylphenyl)methyl]acetamide
4-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
(2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-5-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(3aS,4R,9bS)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-1-(pyrimidin-5-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-1-(pyrimidin-5-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(2R,3S,4R,5R)-5-[2-amino-5-[[[(1S,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
2-amino-3-[[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S,3S,5R,6R)-3-[2-[3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-6-(2-hydroxypropan-2-yl)-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
1-O-(4-oxoretinoyl)-beta-D-glucuronate
A retinoid glucosiduronic acid anion that is the conjugate base of 1-O-(4-oxoretinoyl)-beta-D-glucuronic acid arising from deprotonation of the carboxy group; major species at pH 7.3.
JNJ-42226314
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain[1].